ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$10.2

Market cap

$1.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.8

Enterprise value

$1.2B

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights
Arcutis Biotherapeutics's equity has surged by 154% QoQ and by 61% YoY
ARQT's gross profit has surged by 81% since the previous quarter

Key stats

What are the main financial stats of ARQT
Market
Shares outstanding
115.76M
Market cap
$1.18B
Enterprise value
$1.2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.39
Price to sales (P/S)
10.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.25
Earnings
Revenue
$106.39M
EBIT
-$183.9M
EBITDA
-$182.01M
Free cash flow
-$198.66M
Per share
EPS
-$2.8
Free cash flow per share
-$1.79
Book value per share
$2.32
Revenue per share
$0.96
TBVPS
$4.25
Balance sheet
Total assets
$478.54M
Total liabilities
$253.6M
Debt
$206.74M
Equity
$224.94M
Working capital
$420.75M
Liquidity
Debt to equity
0.92
Current ratio
9.89
Quick ratio
9.34
Net debt/EBITDA
-0.09
Margins
EBITDA margin
-171.1%
Gross margin
93%
Net margin
-204.4%
Operating margin
-184.7%
Efficiency
Return on assets
-60.7%
Return on equity
-197.3%
Return on invested capital
-47.1%
Return on capital employed
-42.6%
Return on sales
-172.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
3.55%
1 week
-4.4%
1 month
20.14%
1 year
-2.76%
YTD
215.79%
QTD
9.68%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$106.39M
Gross profit
$98.93M
Operating income
-$196.46M
Net income
-$217.42M
Gross margin
93%
Net margin
-204.4%
The operating margin has soared by 96% YoY and by 54% from the previous quarter
Arcutis Biotherapeutics's net margin has surged by 96% YoY and by 54% QoQ
ARQT's gross profit has surged by 81% since the previous quarter
The company's revenue has surged by 78% QoQ

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
4.39
P/S
10.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.25
ARQT's EPS has soared by 50% YoY and by 26% QoQ
Arcutis Biotherapeutics's equity has surged by 154% QoQ and by 61% YoY
The stock's price to book (P/B) is 20% less than its last 4 quarters average of 5.5 and 4.6% less than its 5-year quarterly average of 4.6
The company's revenue has surged by 78% QoQ
The price to sales (P/S) is 40% lower than the last 4 quarters average of 17.8

Efficiency

How efficient is Arcutis Biotherapeutics business performance
ARQT's ROS has soared by 96% YoY and by 55% QoQ
The ROE has grown by 33% from the previous quarter but it has contracted by 23% YoY
The company's return on invested capital rose by 28% YoY and by 19% QoQ
ARQT's return on assets is up by 24% year-on-year and by 23% since the previous quarter

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 89% greater than its total liabilities
Arcutis Biotherapeutics's quick ratio has increased by 46% QoQ
The current ratio has grown by 40% from the previous quarter
Arcutis Biotherapeutics's debt is 8% lower than its equity
Arcutis Biotherapeutics's equity has surged by 154% QoQ and by 61% YoY
ARQT's debt to equity has dropped by 60% since the previous quarter and by 37% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.